$RENB News: RenovaroCube Receives Approval of Lumina

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams Lee Adams #98138
224
$RENB News: RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

LUMINA is an Advanced Minimal Residual Disease Detection Platform for Lung Cancer Harnessing the Power of Multi-omics Biomarkers and AI


LOS ANGELES and AMSTERDAM, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced its subsidiary RenovaroCube (the ‘Cube’), a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, received grant funding approval for the Lumina project from the Eurostars funding program after review by an independent expert panel.

Eurostars is part of the European Partnership on Innovative SMEs (Small and Medium-sized Enterprises). The partnership is co-funded by the European Union through Horizon Europe. Eurostars is the largest international funding program for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialization, with over €250M in expected public-private investment each year.

The Lumina project aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.

“This award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization,” said David Weinstein, Chief Executive Officer of Renovaro. “In partnership with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech, the Lumina project is focused on improving lung cancer patient survival. Over 5.7 million lung cancer cases are treated or monitored globally each year, and of all curatively treated lung cancer patients, 60% will relapse. Lumina represents a significant opportunity to address this critical issue, and we look forward to continuing work with our partners to bring this product to market.”

A High-Performance Platform for Better Outcomes

The objective of the LUMINA project is to develop a cutting-edge platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies combined with multi-omics biomarker technology, represent a revolutionary approach. The LUMINA project’s AI-powered platform capitalizes on this potential, aiming to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.

Collaborative Expertise

The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB, and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, leveraging the analysis of cell-free DNA and RNA to ensure the platform’s success.

About Renovaro

Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

About RenovaroCube

RenovaroCube is a pioneer in AI-based molecular diagnostics, committed to revolutionizing healthcare through advanced data analysis. Its platform integrates cutting-edge AI capabilities with state-of-the-art HPC infrastructure to provide unparalleled insights into multi-omic data for early detection of diseases based on non-invasive testing using liquid biopsy (blood).

RenovaroCube’s AI platform is purpose-built to process and analyze multi-omic molecular data, facilitating the discovery of biomarkers critical for early cancer detection, monitoring, and treatment personalization. Originally developed for the fintech sector, this platform is being reengineered for healthcare, offering:

Sequence Processing: Transform raw molecular data from patient samples into clean, analyzable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
Biomarker Discovery: Harness unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
AI Factory: Employ sophisticated machine learning models to predict cancer presence, origin, and stage based on extracted biomarker features. These models are trained on vast datasets to enhance accuracy and reliability, supporting early detection and personalized treatment strategies.
Precision Diagnostics: Offer an interactive interface for visualizing data, generating comprehensive clinical reports, and delivering actionable insights across various omic layers and biomarkers. This interface empowers healthcare professionals to make informed decisions with confidence.
About Flomics Biotech, S.L.

Flomics https://www.flomics.com/ is a fast-growing biotech company based in Barcelona, operating in the genomics and liquid biopsy space. Flomics’ objective is to develop a revolutionary diagnostic blood test based on Next-Generation Sequencing (NGS) of cell-free RNA, suitable for the early detection of different complex diseases, in particular cancer. Additionally, as CRO, Flomics also offers the following services: biomarker discovery (on tissue and biofluids), support on bioinformatic analysis and an intuitive web-based platform suitable for the analysis of NGS data (Stratus). The team at Flomics has a strong background in RNA and liquid biopsy, as well as advanced bioinformatics analysis methods.

About Uppsala Universitet

Uppsala University is the first university in the Nordic countries and a world-class research institution. The Department of Immunology, Genetics and Pathology is dedicated to advancing cancer diagnostics and treatment through the study of molecular changes associated with cancer. The research aims to harness measurable molecular information to improve diagnosis and therapy, with a strong focus on developing liquid biopsy-based diagnostic tests. A key initiative is the U-CAN project, which provides a unique biobank of high-quality clinical samples and data from cancer patients to support translational research. This effort, combined with cutting-edge molecular biology and clinical expertise, underscores the university's commitment to transforming cancer care.

About Oncodia AB

Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. Oncodia is committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Their focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Investor Relations

Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us

For media inquiries, please contact:

karen@renovarocube.com and STarsh@Renovarogroup.com

https://www.globenewswire.com/newsroom/ti?nf=...IxMjA2Nzk=
https://ml.globenewswire.com/media/ZmQxZTY1ZD...ro-Inc.png

Source: Renovaro Inc
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 110

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 36

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 12

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 72

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 68

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 148

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Cooling Garment Enhances Comfort and Safety

Updated Category News Views 195

Innovative Cooling Garment Enhances Comfort and Safety An inventive idea emerges from Pittsburgh, where a passionate creator from Yonkers has designed a unique garment to provide comfort during hot weather. This innovative attire, aptly named the GAIT, offers a cooling effect that surrounds wearers, ensuring they stay safe and comfortable no matter the temperature. The...

Continue Reading
Discovering Next-Gen Oncology Treatments at the ASH Meeting

Updated Category News Views 229

Innovative Presentations from Nurix Therapeutics NURIX Therapeutics, Inc. (NASDAQ: NRIX), a pioneering biopharmaceutical company dedicated to transforming cancer treatment, is set to showcase its significant advancements at a renowned medical meeting. Updated clinical data from the NX-5948-301 Phase 1a/1b trial has been selected for presentation at the 67th American...

Continue Reading
OU Health Partners with Razom to Transform Surgical Training

Updated Category News Views 264

OU Health and Razom Enhance Humanitarian Surgical Training In an inspiring collaboration, OU Health has recently welcomed a significant cohort of Ukrainian surgeons into its humanitarian training program, marking an important milestone in providing essential surgical training for those addressing complex trauma injuries. Expanding the Program The program, which has just...

Continue Reading
Investors Urged to Act: Lead the Charge Against Sarepta

Updated Category News Views 150

Investors May Have A Path Forward Against Sarepta Therapeutics For those who invested in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and have faced significant losses, recent developments present an opportunity to take action. There exists a growing concern regarding the safety implications of one of the company’s leading products, raising questions about transparency and...

Continue Reading
Lindian's Bold Leap into Rare Earths Processing

Updated Category News Views 58

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Continue Reading